Objective: To examine the effect of nucleotide (NT)-supplemented cow's milk-based formula on growth and biochemical indices of immune function in healthy infants. Design: Randomized controlled trial (RCT) of formula-fed term infants allocated to control formula with an innate level of NT at 10 mg/l (n ¼ 102), or formula fortified with NT at 33.5 mg/l (n ¼ 98). A parallel group of 125 breastfed infants followed the same protocol as a reference. Outcome measures: Growth was assessed at enrolment, 7 weeks, 4 months and 7 months of age. Natural killer cell activity, cytokine production and lymphocyte subpopulations were assessed at 7 weeks of age. Antibody responses to diphtheria toxoid, tetanus toxoid and Haemophilus influenzae type b (Hib) immunizations were measured at 7 months of age. Results: NT supplementation did not influence the growth of formula fed infants or any markers of immunity measured at 7 weeks of age. Antibody responses to tetanus toxoid were higher in the NT-supplemented group (n ¼ 68) compared with the control group (n ¼ 70) at 7 months of age (median (5th, 95% percentile): 1.57(0.42, 3.43) vs 1.01(0.41, 4.66) IU/ml, Po0.03). A difference between treatments was seen in response to diphtheria toxoid but this effect disappeared when adjusted for hepatitis B immunization at birth. There was no effect of treatment on antibody responses to Hib immunization. Conclusions: Supplementation of formulas with NT at 33.5 mg/l resulted in a modest improvement in antibody response consistent with RCTs that used higher levels of NT supplementation. Whether this translates to clinical benefits in well-nourished infants requires further study.
Introduction
Animal and in vitro studies have shown that dietary nucleotides (NT) can affect immune function and may have beneficial effects on gastrointestinal tract growth and maturation (reviewed in Carver, 1999; Gil, 2002) . Human milk contains higher amounts of non-protein nitrogen as NT, nucleosides and nucleic acids compared with bovine milk from which most infant formulas are made (Leach et al., 1995; Carver, 1999) . In some regions of the world, the recommended maximum content of NT and NT precursors in term infant formula is 107 mg/l (16 mg/100 kcal), a value similar to the upper level reported for human milk (Raiten et al., 1998; Aggett et al., 2003) . However, in other regions, regulations limit supplementation levels to 33.5 mg/l (5 mg/ 100 kcal), which is equivalent to the free NT concentration in human milk (Raiten et al., 1998; Aggett et al., 2003; Food Standards Australia and New Zealand, 2004) . Differing recommendations and changes in the method of analysis of human milk NT have inevitably led to several levels of supplementation of commercial term formulas, which have also formed the basis of clinical studies.
Some randomized controlled trials (RCTs) involving formula-fed infants have reported beneficial effects of NT supplementation on various components of the immune system (Carver et al., 1991; Pickering et al., 1998; Buck et al., 2004; Schaller et al., 2004) , the incidence of diarrhoea (Yau et al., 2003) , intestinal microflora (Gil et al., 1986) , growth of infants born small for gestational age (Cosgrove et al., 1996) and the synthesis of long-chain polyunsaturated fatty acids (LCPUFA) (DeLucchi et al., 1987) . However, other RCTs have been unable to confirm the reported beneficial effects of NT supplementation (Balmer et al., 1994; Woltil et al., 1995; Yau et al., 2003) . Many of the trials had small sample sizes and inadequate information to assess trial quality, hence making it difficult to establish the clinical efficacy of NT supplementation.
Our pragmatic intervention trial was designed to investigate the effect of term infant formula supplemented with NT as marketed in Australia (33.5 mg/l 5 0 -monophosphates; 5 mg/100 kcal) on growth and a number of outcome measures that may be indicative of immune capacity in infancy in comparison with non-NT-supplemented formula. The protocol was designed to mirror current practice with regard to introduction of solids and implementation of the immunization schedule. Primary outcome measures included weight at 4 months of age, and lymphocyte subsets (CD4 þ cells, CD8 þ cells, natural killer (NK) cells), NK cell activity and interleukin 2 (IL-2) production at 7 weeks of age. Secondary outcomes included weight, length and head circumference measurements at 7 weeks and 7 months, length and head circumference measurements at 4 months, tolerance of formula feeds at 7 weeks, 4 months and 7 months, lymphocyte subsets (T cells, B cells, CD45RA þ cells, CD45RO þ cells, CD25 þ cells) and interferon g (IFNg) production at 7 weeks and plasma concentration of tetanus, diphtheria and Hib polyribosylribitol (PRP) antibodies at 7 months. A parallel group of breastfed infants was included as a reference.
Subjects and methods

Subjects
Mothers with eligible infants were recruited from the postnatal ward at the Women's and Children's Hospital (WCH), Adelaide, over the period from March 2000 to August 2001 according to the protocol approved by the WCH Research Ethics Committee. Infants were eligible if they were born at term (X37 weeks gestation) and had a birth weight X2500 g. Infants were excluded if they had major congenital deformities or illnesses, confirmed infection in the neonatal period requiring antibiotic therapy or if their mother had diabetes requiring insulin during pregnancy. Infants allocated to the formula feeding groups had mothers who had decided to exclusively formula feed from birth. Mothers who intended to breastfeed for at least 7 months were approached for enrolment into the reference breastfed group. Following written informed consent, we collected baseline socio-demographic data such as parity, number of children in the household, maternal smoking in pregnancy, maternal and paternal education, and maternal and paternal occupation.
Randomization and blinding
Formula-fed infants were randomly assigned to one of four formula codes corresponding to two different formulas. The randomization schedule was computer-generated and stratified according to sex and number of children in the household (0 or X1) by an independent consultant not involved in the trial. Multiple births formed a single randomization unit assigned according to the first born. Assignment to the infant's feeding regimen was by sequentially numbered (within each stratum), opaque, sealed envelopes. Trial participants and study personnel had no knowledge of the next assignment prior to obtaining consent.
Treatments
Infants in the control group received standard wheyadapted, cow's milk protein-based S26 (Wyeth Nutrition) in powder form to provide 67 kcal/100 ml and an innate level of NT at 10 mg/l (1.5 mg/100 kcal). Infants in the treatment group (NT þ ) received the same whey-adapted, cow's milk protein-based S26 in powder form to provide 67 kcal/ 100 ml and fortified with cytidine monophosphate (CMP) at 17.3 mg/l (2.58 mg/100 kcal), uridine monophosphate (UMP) at 6.6 mg/l (0.99 mg/100 kcal), adenosine monophosphate (AMP) at 4.4 mg/l (0.66 mg/100 kcal), inosine monophosphate (IMP) at 3.1 mg/l (0.46 mg/100 kcal) and guanosine monophosphate (GMP) at 2.2 mg/l (0.33 mg/ 100 kcal). The level of each of these nucleotide 5 0 -monophosphates falls within the minimum and maximum amounts permitted by the Australia New Zealand Food Standards Code (Food Standards Australia and New Zealand, 2004) . Both test formulas contained the same amount of protein (15 g/l), carbohydrate (72 g/l) and fat (36 g/l) including linoleic acid (16.2% of total fatty acids) and alpha-linolenic acid (1.5% of total fatty acids) but no added LCPUFA.
Mothers were asked to feed their infant their assigned study formula as the only milk source until 7 months of age, and for breastfed infants, breastfeeding was strongly encouraged for the entire 7-month feeding period. The use of solid foods was strongly discouraged during the first 4 months of the study. Intake of cow's milk products in any form, juice or solid foods was recorded by the mothers using a daily diary provided by the study. Information from the daily record was documented in case report forms by study personnel at each home visit (2 weeks, 4 months), clinic appointment (7 weeks, 7 months) and as part of monthly telephone contact throughout the study (1, 3, 5 and 6 months).
Compliance with the dietary intervention was categorized as follows: High: X80% of milk feeds throughout the study period were study formula; Low: o80% of milk feeds throughout the study period were study formula. Similarly, breastfeeding compliance was categorized as follows: High: X80% of the milk feeds were breastfeeds; Low: o80% of the milk feeds were breastfeeds.
Clinical assessments
Weight, length and head circumference were measured at enrolment (birth-8 days), 7 weeks, 4 months and 7 months of age by staff employed for the purposes of the study. Measurements were conducted at the subject's home unless they were required to return to the WCH for collection of a blood sample. All equipment was portable and used for both home and clinic visits. Bare weight was measured to the nearest 10 g on an electronic scale. Recumbent length (nearest 1 mm) was measured using a standardized length board. Two people conducted each length measurement to ensure proper body alignment and full body extension with dorsiflexed feet. Head circumference (nearest 1 mm) was measured at the largest circumference of the skull using a non-elastic, plastic-coated measuring tape.
Maternal assessment of tolerance of feeds and illness profiles were noted in diaries provided and recorded in case report forms at the home visits, each clinic visit and at each monthly telephone contact. Symptoms of respiratory illness recorded included blocked or runny nose, cough and/ or wheeze, with or without fever. Diarrhoea, with or without vomiting or fever, and vomiting with fever were classified as symptoms of gastrointestinal illness. Diarrhoea was defined as two or more runny stools per day that differed from the infant's usual stool frequency and consistency.
Immunizations
Immunizations against diphtheria, tetanus, pertussis and hepatitis B using the combination vaccine DTPa-hepB (Infanrix-hepB, SmithKline Beecham) were administered to infants at 2, 4 and 6 months of age (8.471.8 weeks, n ¼ 305; 18.372.6 weeks, n ¼ 292; 27.572.7 weeks, n ¼ 276; mean7s.d. Immunisation, 2000) . We therefore tested whether vaccination with HBVax II at birth (i.e. close to randomization) influenced antibody responses at the end of the trial. Immunization with HBVax II at birth had no effect on antibody responses to Hib and tetanus but was associated with reduced antibody responses to diphtheria in the NT-supplemented group at 7 months. Hence, the diphtheria responses are reported as unadjusted and adjusted analyses for HBVax II at birth.
Laboratory assessments
Blood samples (p2 ml) were taken by venipuncture at 7.370.5 weeks of age (prior to the first immunization with DTPa-hepB), for assessment of lymphocyte subsets, NK cell activity and cytokine production. A second blood sample was taken by venipuncture at 31.971.6 weeks of age (3377 days after the third immunization for DTPa and 99713 days after the second immunization for Hib, n ¼ 231) for measurement of antibody concentrations. Samples were taken at these time points to optimize the opportunity to find differences between the treatment groups based on existing literature (Carver et al., 1991; Pickering et al., 1998) . All blood samples were taken at the WCH and transported to the laboratory for processing within 2-3 h of collection. Immunophenotyping, NK activity assays and cell culture set-up for cytokine production were completed on the day of collection.
Immunophenotyping of lymphocyte subsets was determined by three-colour immunofluorescence flow cytometry on a FACScan instrument using standard instrument parameters and CellQuest software (Becton Dickinson, San Jose, CA, USA) essentially as described previously (Hawkes et al., 1999a) . Lymphocytes were distinguished on the basis of dual scatter parameters and CD45-positive staining and were manually gated to include only lymphocytes in the analysis. The percentage of peripheral blood mononuclear cells (PBMCs) expressing each particular cell-surface antigen is reported.
NK cell activity was determined by measuring cytotoxicity using flow cytometry (methodology adapted from Chang et al., 1993) . Data are presented as lytic units, which represent the number of effector cells ( Â 10 5 ) required to achieve 5% cytotoxicity of 1 Â 10 5 target cells.
To assess cytokine production (IL-2, IFNg), PBMCs were cultured (2 Â 10 6 cells/ml) in 96-well flat-bottomed plates (Greiner Labortechnik, Frickenhausen, Germany) at 371C in the presence or absence of phytohaemagglutinin (PHA, 10 mg/ml; Sigma Aldrich, St Louis, MS, USA) for the measurement of IL-2 or concanavalin A (Con A, 10 mg/ml; ICN Biomedicals Inc., Costa Mesa, CA, USA) for the measurement of IFNg. After 48 h, cells were lysed by one freeze-thaw cycle and the supernatants harvested for analysis of total cytokines (intracellular and secreted). Supernatants were stored at À801C until analysis for IL-2 and IFNg using double antibody sandwich enzyme-linked immunosorbent assays (ELISAs) established in this laboratory using matched pair antibodies and standards from R&D Systems (Minneapolis, MN, USA) (Hawkes et al., 1999b) . Samples with cytokine levels below the level of detection for IL-2 (7.8-62.5 ng/l) and IFNg (7.8-125 ng/l) were assigned a value of half the limit of detection for that assay for statistical calculations. The plasma concentrations of antibodies against tetanus toxoid and diphtheria toxoid were measured by ELISA based on methods previously described (Melville-Smith et al., 1983; Walory et al., 2000) . Toxoid-specific IgG antibodies were quantitated by use of a pooled adult serum standard, a pooled infant serum standard and the appropriate NIBSC external reference antitoxin (National Institute for Biological Standards and Control, Hertfordshire, UK). The concentration of antibody directed against PRP, a component of the capsular polysaccharide coat of Hib, was measured by ELISA based on the method described by Insel and Anderson (1976) . The reference serum used to construct the standard curve was the international reference standard, USFDA human anti-Hib capsular polysaccharide serum. Quality control samples were obtained from serum collected from adult volunteers. Data were analysed using Multicalc s software (PerkinElmer Life Sciences, Boston, MA, USA). Samples with antibody levels below the level of detection for each assay (tetanus and diphtheria, 0.015 IU/ml; Hib, 0.08 mg/ml) were assigned a value of half the limit of detection for statistical calculations.
Sample size and statistics Based on data obtained from our laboratory for immunophenotyping of CD4 þ , CD8 þ and NK cells, sample size calculations indicated that a total of 12-65 infants per group would enable the detection of a 20% difference between groups with 80% power (a ¼ 0.05) (Hawkes et al., 1999a) . We estimated that 30 infants per group would be needed (unpaired data) for NK cell activity and 22 infants per group for IL-2 production (a ¼ 0.05, power 80%) to emulate the differences reported by Carver et al. (1991) . Weight at 4 months (end of milk feeding as the sole source of nutrition) was considered the primary growth end point. A total of 58 infants per group would enable the detection of a weight difference of 500 g between groups with 80% power (a ¼ 0.05).
In order to cover all sample size estimates, we aimed for 70 infants per group to complete the trial. We therefore enrolled approximately 100 infants per group. This allowed for 30% loss due to withdrawals, low compliance and incomplete blood collections. A total of 125 breastfed infants were required to ensure that at 7 months at least 70 infants were still receiving greater than 80% of milk feeds as human milk.
The effect of feeding formula with or without NT on markers of immunity and growth was assessed on an intention-to-treat basis. All data were tested for normality of distribution using the Kolmogorov-Smirnov or ShapiroWilk statistic. Growth data were generally normally distributed and differences between the randomized treatment groups were analysed by independent samples t-test. Laboratory markers of immunity (NK activity, cytokine production, immunophenotyping and antibody responses to immunization) were highly skewed and in most cases were found not to be normally distributed following logarithmic transformation. These data were analysed by Mann-Whitney U-test with Monte Carlo correction. Results are displayed as medians and 5th and 95th percentiles. Data relating to tolerance of feeding were included from infants completing the study and differences between groups were determined by Pearson's w 2 tests. Secondary analyses included comparisons between all three feeding groups (including the breastfed reference group) and were performed using oneway analysis of variance (ANOVA) with post hoc analysis using Bonferroni corrections or the Kruskal-Wallis test. All analyses were repeated for the subgroup of infants that achieved high compliance at the time of data collection (as-per-protocol). All analyses were completed using SPSS for Windows 10.0 (SPSS Inc., Chicago, IL, USA).
Results
Characteristics of trial participants A total of 301 eligible formula-fed infants were approached to participate in the study. A total of 200 mothers agreed to participate and were allocated either to the control group (n ¼ 102) or the NT þ group (n ¼ 98) (Figure 1 and Table 1 ). Although 98/102 (96%) and 88/98 (90%) in the control and NT þ groups, respectively, completed the trial, immune indices were not available from all infants largely because of incomplete blood collection, mothers refusing consent for the blood sample and poor compliance with the immunization schedule (at 7 months) (Figure 1 ).
Blood samples suitable for analysis of some markers of immune status were collected from 262/325 (81%) infants at 7 weeks of age and 231/325 (71%) infants at 7 months of age. Despite this, we achieved our sample size estimates for all outcomes and at least 90% of all infants at each assessment were highly compliant (receiving at least 80% of their milk feeds as study formula). A total of 125 breastfed infants were recruited to the reference group. Data on feeding practices and growth measurements were collected from all infants in the breastfed group remaining in the study at 7 weeks of age (119/125; 95%). As expected, the number of highly compliant breastfed infants decreased throughout the study 
Blood sample at 7 mo (n = 70/102, 69%) Blood sample at 7 mo (n = 68/98, 69%) 7 months Growth (n = 88/98, 90%) 7 months Growth (n = 98/102, 96%) Incomplete blood sample, n =6 Mother refused consent, n =4 Not compliant with immunization, n = 18
Incomplete blood sample, n=9 Mother refused consent, n=3 Did not attend appointment, n =2 Not compliant with immunization, n =7 Withdrawn, n =1 Lost to follow-up, n =1
Withdrawn, n=1
Did not attend appointment, n =1 Lost to follow-up, n =2 Figure 1 Trial profile for formula-fed infants. Trial profile for breastfed infants was as follows: 125 breastfed infants were recruited to the reference group from 300 eligible mothers approached. Data on feeding practices and growth measurements were collected from all infants in the breastfed group remaining in the study at 7 weeks of age (119/125; 95%). Laboratory analyses were not performed on 29 infants for the following reasons: the infant had withdrawn from the study (6), did not attend appointment (1), incomplete blood sample (17), mother refused consent (5). A total of 116 (93%) breastfed infants completed the study (withdrawn, n ¼ 8; lost to follow-up, n ¼ 1). Laboratory analyses at 7 months were not performed on a further 23 subjects for the following reasons: did not attend appointment (3), incomplete blood sample (8), mother refused consent (3), not compliant with immunization (9).
to 98/119 (82%) at 7 weeks and 69/117 (59%) at the end of the study.
At study entry, there were no differences between the randomized formula groups for perinatal characteristics or socio-demographic variables (Table 1) . However, on average, the breastfed infants had gestational ages that were greater than formula-fed infants (Po0.05). Breastfed infants were also heavier and longer at birth than formula-fed infants (Po0.05) and lactating women were less likely to smoke during pregnancy (Po0.05) and were more socially advantaged than women who chose to formula feed (Po0.05) ( Table 1) .
Solids were introduced into the diet of 71% (137/191) of formula-fed infants by 4 months of age and there was no difference in the rate of introduction of weaning foods or type of weaning foods between the treatment groups (data not shown). Fewer infants in the breastfed reference group had received solids by 4 months of age (66/116, 57%). By 7 months of age, all infants in the study were receiving weaning foods in accordance with usual and recommended feeding practices in Australia.
Growth and clinical outcomes
There were no differences in weight, length or head circumference between infants randomly allocated to either NT supplemented or control formula at any assessment (Figure 2 ). At enrolment, breastfed infants were the same age as infants in the formula groups (2.470.1 days) and weighed 3382739 g (n ¼ 124) compared with the formula groups (control group 3266741 g, n ¼ 102; NT þ group 3288744 g, n ¼ 98, P ¼ 0.09). Breastfed infants were longer at enrolment (50.770.2 cm) compared with formula-fed infants (control group 49.970.2 cm; NT þ group 49.870.2 cm, Po0.01) and had a larger head circumference (35.270.1 cm) compared with the control group (34.670.1 cm) and the NT þ group (34.570.1 cm) (Po0.01). The trend for breastfed infants to be proportionately larger than those fed formula continued until 7 weeks of age (weight (g) at 7 weeks: breastfed 5065754, n ¼ 119; control 4874752, n ¼ 99; NT þ 4878763, n ¼ 92, P ¼ 0.02; length (cm) at 7 weeks: breastfed 57.170.2, n ¼ 118; control 56.270.2, n ¼ 99; NT þ 56.070.2, n ¼ 91, Po0.01; head circumference (cm) at 7 weeks: breastfed 38.970.1, n ¼ 119; control 38.370.1, n ¼ 99; NT þ 38.570.1, n ¼ 92, Po0.01). There were no differences between any of the groups by 4 months of age.
There was no difference in the incidence of constipation, gastrointestinal illness or respiratory illness between the formula groups (intention-to-treat, data not shown). However, following subgroup analysis of the compliant formula-fed infants (as-per-protocol), we did observe that by 7 months more infants allocated to the NT þ formula had symptoms of at least one respiratory illness (60/82 (73%)) compared with infants fed control formula (51/89 (57%)) (P ¼ 0.04). There were no differences in the reported incidence of gastrointestinal illness or respiratory illness when all three feeding groups were included in the analysis (intention-to-treat or as-per-protocol). The mothers of breastfed infants reported fewer episodes of constipation than did the mothers of infants in the formula-fed groups at all time points (8-14% compared with 23-29%, Po0.01). There were no other differences between breastfed and formula-fed infants in growth and clinical outcomes.
Immunophenotyping
There were no significant differences between the formula groups for any of the eight lymphocyte subpopulations tested at 7 weeks of age when all results from formula-fed infants were included in the analysis, that is, intention-totreat (Table 2) or following subgroup analysis of compliant There were no significant differences between the two randomized groups for any of the variables described. Control, unsupplemented formula; NT þ , nucleotidesupplemented formula.
a Gestational age, parity and number of children in the home are given as median (5th, 95th percentile). b Birth measurements are given as mean7s.e.m.
c Ranked according to Daniel, 1983. Dietary nucleotides and infant immune function JS Hawkes et al infants (as-per-protocol; Table 3 ). The only difference observed was in the subgroup analysis including compliant breastfed and formula-fed infants (three-way comparison, asper-protocol) where there was a difference in the percentage of CD45RO cells (10 (5, 43) in the breastfed group (n ¼ 68) compared with 9 (5, 21) in the control group (n ¼ 72) and 8 (5, 19) in the NT þ group (n ¼ 70), P ¼ 0.05, Kruskal-Wallis test).
NK cell activity
The NK cell cytotoxicity assay was performed on 154 blood samples collected from infants at 7 weeks of age. There were no differences between the groups following analysis of the formula groups alone or all three feeding groups as intention-to-treat (18.3 (4.1, 46.8) in the control group (n ¼ 47), 20.6 (6.4, 65.4) in the NT þ group (n ¼ 48) and 16.2 (4.2, 55.9) in the breastfed group (n ¼ 59)) or as-per-protocol (data not shown; Table 3 ).
Cytokine production
Values for IL-2 and IFNg production in mononuclear cell cultures, under stimulated conditions, are shown in Table 4 . Very little (median: 8 ng/l) of either cytokine was produced in the absence of mitogenic stimulation (data not shown). Following stimulation, the production of both cytokines was increased (Po0.01, Wilcoxon's signed ranks test) but there were no differences between any of the feeding groups. Analysis of the compliant subgroups also showed that there were no differences between the control and NT-supplemented groups but that IL-2 production by the breastfed group was less than the control group (1188 (5, 11 476) ng/l in the control group (n ¼ 45) compared with 483 (16, 8294) ng/l in the NT þ group (n ¼ 47) and 120 (4, 7171) ng/l in the breastfed group (n ¼ 37), P ¼ 0.03, KruskalWallis test).
Immunization responses
Tetanus. Infants in the NT þ formula group had higher plasma IgG antibody concentrations to tetanus toxoid compared with infants in the control group (Table 5 , intention-to-treat). This difference was maintained following subgroup analysis of compliant infants (as-per-protocol; 1.59 (0.42, 3.52) IU/ml in the NT þ group (n ¼ 65) compared with 1.03 (0.41, 4.68) IU/ml in the control group (n ¼ 67), P ¼ 0.04). All formula-fed infants had tetanus toxoid antibody titres greater than 0.1 IU/ml, which is the level Figure 2 Weight (a), length (b) and head circumference (c) of formula-fed infants participating in the study at enrolment, 7 weeks, 4 months and 7 months of age. Box plots show medians and upper and lower quartiles, with the 10th and 90th percentiles extending either side. Infants in the unsupplemented formula (control) group are shown in the white boxes and infants in the NT-supplemented formula (NT þ ) group are shown in the shaded boxes. There were no significant differences between treatment groups for any of the variables described. The age (mean7s.d.) of the infants also did not differ significantly between the groups (270.1 days in the control group (n ¼ 102) compared with 270.2 days in the NT þ group (n ¼ 98) at enrolment, 5170.4 days in the control group (n ¼ 99) compared with 5170.4 days in the NT þ group (n ¼ 92) at 7 weeks; 12170.5 days in the control group (n ¼ 97) compared with 12170.4 days in the NT þ group (n ¼ 92) at 4 months, and 22171.0 days in the control group (n ¼ 98) compared with 22371.2 days in the NT þ group (n ¼ 88) at 7 months).
considered protective when the titre is determined by ELISA (Galazka, 1993) . The breastfed group did not differ from either formula group. Diphtheria. Our initial unadjusted analysis indicated that infants in the NT þ group had a higher antibody titre to diphtheria toxoid than the control group (P ¼ 0.05; Table 5 ). Data were analysed on an intention-to-treat basis. There were no significant differences between the two randomized groups for any of the variables described (Mann-Whitney U-test), or when all three groups were included in the analysis (Kruskal-Wallis test). Control, unsupplemented formula; NT þ , nucleotidesupplemented formula. 
Control, unsupplemented formula; NT þ , nucleotide-supplemented formula; BF, reference breastfed group; ND, no difference. a All data collected included in the analysis. b Analysis repeated for the subgroup of infants that achieved high compliance at the time of data collection (X80% milk feeds were study formula or breastfeeds as appropriate). The median level of either cytokine did not exceed the lowest level of detection (8 ng/l) in the absence of in vitro stimulation (data not shown). Data were analysed on an intention-to-treat basis. There were no significant differences between the two randomized groups for any of the variables described (Mann-Whitney U-test), or when all three groups were included in the analysis (Kruskal-Wallis test). Control, unsupplemented formula; NT þ , nucleotide-supplemented formula.
This included 8/70 (11%) infants in the control group and 4/ 68 (6%) infants in the NT þ group having plasma diphtheria toxoid antibody titres less than 0.1 IU/ml (P ¼ 0.37, Pearson's w 2 test). A much larger sample size would be required to determine whether the difference between the randomized groups is statistically and clinically significant on a population basis. Adjusting for HepB immunization at birth negated the effect of NT supplementation on diphtheria antibody titre at 7 months (P ¼ 0.78). There were no differences between the formula and breastfed groups (Table 3) .
Hib PRP. There were no differences between formula groups in the plasma concentration of IgG antibody to Hib PRP (intention-to-treat or as-per-protocol). The three-way comparison revealed that breastfed infants had a significantly lower plasma concentration of IgG antibody in response to Hib PRP immunization than both groups of formula-fed infants at 7 months of age (Po0.01, Kruskal-Wallis test; Table 3 ). This difference was maintained following subgroup analysis of the compliant infants (0.68 (0.04, 19.46 ) mg/ml in the breastfed group (n ¼ 55) compared with 1.80 (0.26, 21.10) mg/ml in the NT þ group (n ¼ 65) and 2. 49 (0.31, 33.27 ) mg/ml in the control group (n ¼ 67), Po0.01). There was no difference between the formula feeding groups in the number of infants with Hib PRP antibody concentrations 41.0 mg/ml (54/70 (77%) in the control group compared with 47/68 (69%) in the NT þ group, Pearson's w 2 , P ¼ 0.34). A lower proportion of breastfed infants achieved antibody concentrations to Hib PRP greater than 1.0 mg/ml (47/93, 51%, Po0.01). Overall, the proportions of infants with antibody levels 40.15 or 41 mg/ml after two injections were 97 and 64%, respectively, which is comparable to reported data with PRP-OMP (Decker et al., 2000) .
Discussion
This comprehensive study addresses the question of whether supplementation of infant formula with 33.5 mg/l (5 mg/ 100 kcal) free NT influences the growth and immunological development of infants born healthy and at term. We report that NT supplementation did not influence any cellular markers of immune status at 7 weeks of age including the distribution of the major lymphocyte subpopulations of peripheral blood, which were primary outcomes in this trial and are often used to reflect changes in immune development. These findings agree with those of other RCTs of NT supplementation that assessed cow's milk-based formula in term infants , soy-based formula in term infants ) and cow's milk-based formula in preterm infants (Navarro et al., 1999) at a range of doses (from 11.7 mg/l (Navarro et al., 1999) to 72 mg/l Buck et al., 2004) ). NT-associated differences in memory/effector T-cell subtypes and NK cell subtypes have been reported ; however, those specific populations were not measured in our study. The subgroup analysis of lymphocyte subsets including the breastfed reference group revealed that fully breastfed infants had a greater percentage of CD45RO cells than the NT þ group. Prevalence of memory/effector cells (CD45RO) relative to naïve T cells (CD45RA) is indicative of immune maturation, which is in accordance with previous observations that breastfed infants display immunophenotypic changes consistent with greater maturity in the development of their immune system (Hawkes et al., 1999a) . The relative frequencies of each lymphocyte population in this study fall within the ranges reported elsewhere for the relevant age group (Erkeller-Yuksel et al., 1992; Heldrup et al., 1992; ComansBitter et al., 1997) . Collectively, these data suggest that reported changes in immune function in response to dietary NT are not mediated by shifts in the major T-and B-cell populations.
The production of IL-2 and the activity of NK cells have been reported to be enhanced by NT supplementation. These data come from a single clinical trial with a small number of infants in each feeding group (n ¼ 13-15) (Carver et al., 1991) . We could not detect an effect of NT supplementation on the production of IL-2 or IFNg by mitogen-stimulated PBMCs, or in the NK cell activity of cells collected from Data were analysed on an intention-to-treat basis. Differences between the two randomized groups were determined by Mann-Whitney U-test (P-values as shown). There were no differences between the groups for diphtheria or tetanus when all three groups were included in the analysis (Kruskal-Wallis test). Breastfed infants had lower antibody responses to Hib PRP immunization than both groups of formula-fed infants (Kruskal-Wallis test, Po0.01). Control, unsupplemented formula; NT þ , nucleotide-supplemented formula.
a Unadjusted P-value. b Ranked data were adjusted for immunization with HBVax II at birth using univariate analysis of variance.
infants in the formula-fed groups. In addition, the production of IL-2 in the fully breastfed infants in our study was significantly lower than that of the control formula-fed infants. Given the considerable variation in our data as well as those of Carver et al. (1991) , it is difficult to make robust conclusions regarding the effect of dietary NT on these measures of immune function. In our RCT, the antibody responses to tetanus and diphtheria toxoid vaccines were higher in the NT-supplemented group compared with control. Inclusion of hepatitis B at birth as a potential confounder negated the effect of NT supplementation on diphtheria response but not tetanus. Although we have no explanation for this finding, it may indicate that addition of early immunizations to a schedule can modulate infant responsiveness to other vaccines, as has been seen with the use of some combination vaccines (McVernon et al., 2003) . There is other evidence of an effect of supplemental NT on infant antigen-specific antibody responses to immunization (Pickering et al., 1998; Schaller et al., 2004) . In both of those studies, term infants received cow's milk formula supplemented with 72 mg NT/l (10.9 mg/ 100 kcal), there were differences in the timing and types of vaccinations used and they reported positive effects to some antibody titres but not others. For example, Pickering et al. (1998) reported elevated responses to diphtheria toxoid and Hib PRP following NT supplementation but not to tetanus toxoid or oral poliovirus vaccine whereas significant NTassociated increases in responses to oral poliovirus and not to other vaccines were shown in the recent study by Schaller et al. (2004) . Collectively, these data suggest that supplemental NT may improve infant humoral immune status; however, there is no indication of a dose response or consistency of specificity of response. The clinical benefit to well-nourished infants requires further study because the vast majority of infants had antibody titres above the accepted cutoff for protection against disease (Galazka, 1993) .
The sample size in our trial was large and only 6% of infants were withdrawn or lost to follow-up. This high retention of enrolled infants taken together with the fact that 66% of all eligible formula-fed infants participated and the pragmatic trial protocol support the internal and external validity of the trial results. Although some blood samples were missed, this was a random event, which is evidenced by the fact that the characteristics of infants from whom blood samples were not available were not different from infants included in the analyses of immune markers (data not shown).
It has been proposed that NT supplementation results in improvements in gut microflora (Gil et al., 1986) and incidence of diarrhoea (Brunser et al., 1994; Pickering et al., 1998; Yau et al., 2003) . However, the data are conflicting (Balmer et al., 1994; Ostrom et al., 2002) . There are few data from well-controlled RCTs to demonstrate that NT supplementation of term infants protects against infection. A recent RCT suggested a negative effect of NT supplementation on the incidence of upper respiratory tract infections throughout the first year of life (Yau et al., 2003) . We also showed more reports of respiratory illness in NT-supplemented, highly compliant, formula-fed infants at 7 months of age compared with control formula-fed infants. These data are difficult to interpret because the incidence of respiratory illness in breastfed infants was intermediate between the two formula-fed groups, but deserve further investigation in studies that are specifically designed to assess illness profiles. No study to date, including ours, has reported an NT effect on growth in term infants who are born appropriate for gestational age (reviewed in Carver and Walker, 1995) .
In conclusion, supplementation of cow's milk-based formula with NT at 33.5 mg/l resulted in a modest improvement in some antibody responses in our population of healthy term infants, with no effect on other markers of immune status and growth. In 1998, the Expert Panel on Assessment of Nutrient Requirements for Infant Formulas concluded that the preliminary evidence of beneficial effects from NT supplementation was intriguing but urged more research in the area (Raiten et al., 1998) . Although interpretation of the recently published trials is difficult, there is some evidence that supplementation may enhance humoral immunity in well-nourished infants. We speculate that the most benefit may be obtained by high-risk infants such as those born prematurely (Martinez-Augustin et al., 1997), those from socially disadvantaged backgrounds (Brunser et al., 1994) or those born small for gestational age (Cosgrove et al., 1996) .
